MAD2L1

Across TCGA pan-cancer cohorts, MAD2L1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MAD2L1 data layer compared with 30 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher MAD2L1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAD2L1 expression acts as an unfavorable survival marker.

THYM and PRAD are the cancer types where MAD2L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	DFS	Median	All	0.123	0.871	<.001	12	view →
PRAD	DFS	Median	All	0.646	0.886	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MAD2L1–THYM (DFS)

Open the THYM breakdown →